Reproductive health considerations for IDH-mutant glioma patients considering IDH inhibitor therapy: A retrospective cohort study
According to our institutional data, conversations regarding IDHi reproductive risks are not generally documented, contrary to guideline recommendations. Future studies are required to better understand the impact of IDHi therapy on fertility and fetal development.
Authors
- L. Nicolas Gonzalez Castro (ORCID: https://orcid.org/0000-0001-7699-5188)
- Ethan A. Wetzel (ORCID: https://orcid.org/0000-0003-1944-0279)
- Tyler Lanman (ORCID: https://orcid.org/0000-0001-8746-282X)
- Kajal Verma (ORCID: https://orcid.org/0000-0001-9159-9722)
Institutions
- Harvard University (US)
- Palo Alto University (US)
- University of Washington (US)
- Center for Neuro-Oncology (US)
- Dana-Farber Cancer Institute (US)
- Global Cancer Institute (US)
- Mass General Brigham (US)
- Stanford University (US)
Publication Details
- Journal
- Neuro-Oncology Practice
- Published
- 2025-07-14
- DOI
- https://doi.org/10.1093/nop/npaf071
- Primary Topic
- Prostate Cancer Treatment and Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00